Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects

Journal of Clinical Investigation

Volumn 122, Issue 10, 2012, Pages 3718-3730

  Ruocco, Maria Grazia ^a,b   Pilones, Karsten A ^a   Kawashima, Noriko ^a   Cammer, Michael ^a   Huang, Julie ^a,c   Babb, James S ^a   Liu, Mengling ^a   Formenti, Silvia C ^a   Dustin, Michael L ^a   Demaria, Sandra ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SORBONNE UNIVERSITÉ   (France)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; MEMBRANE PROTEIN; NATURAL KILLER CELL RECEPTOR NKG2D; RETINOIC ACID EARLY INDUCIBLE 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CD8+ T LYMPHOCYTE; CELL CYCLE ARREST; CELL MOTILITY; CONTROLLED STUDY; FLOW CYTOMETRY; IN VIVO STUDY; IONIZING RADIATION; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TREATMENT OUTCOME; TUMOR IMMUNITY;

ANIMALS; ANTIBODIES, MONOCLONAL; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL MOVEMENT; COMBINED MODALITY THERAPY; CTLA-4 ANTIGEN; CYTOTOXICITY, IMMUNOLOGIC; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; H-2 ANTIGENS; IMMUNOTHERAPY; INTERCELLULAR ADHESION MOLECULE-1; LYMPHOCYTES, TUMOR-INFILTRATING; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; NEOPLASM PROTEINS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; NUCLEAR MATRIX-ASSOCIATED PROTEINS; NUCLEOCYTOPLASMIC TRANSPORT PROTEINS; RECEPTORS, CXCR; TUMOR MICROENVIRONMENT;

EID: 84867182261     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI61931     Document Type: Article

References (86)

1. Galon J, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960-1964. (Pubitemid 44498003)
2. Mrass P, et al. Random migration precedes stable target cell interactions of tumor-infiltrating T cells. J Exp Med. 2006;203(12):2749-2761. (Pubitemid 44833350)
3. Ng LG, Mrass P, Kinjyo I, Reiner SL, Weninger W. Two-photon imaging of effector T-cell behavior: lessons from a tumor model. Immunol Rev. 2008;221:147-162. (Pubitemid 351230121)
4. Boissonnas A, Fetler L, Zeelenberg IS, Hugues S, Amigorena S. In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor. J Exp Med. 2007;204(2):345-356. (Pubitemid 46294550)
5. Breart B, Lemaître F, Celli S, Bousso P. Two-photon imaging of intratumoral CD8+ T cell cytotoxic activity during adoptive T cell therapy in mice. J Clin Invest. 2008;118(4):1390-1397. (Pubitemid 351500432)
6. FDA approves new treatment for a type of late-stage skin cancer [press release]. U.S. Food and Drug Administration Web Site. http://www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/ucm1193237.htm. Published March 25, 2011. Accessed July 27, 2012.
7. Peggs KS, Quezada SA, Allison JP. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. Immunol Rev. 2008;224:141-165.
8. van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med. 1999;190(3):355-366.
9. Mokyr MB, Kalinichenko T, Gorelik L, Bluestone JA. Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice. Cancer Res. 1998;58(23):5301-5304. (Pubitemid 28551104)
10. Demaria S, et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res. 2005;11(2 pt 1):728-734. (Pubitemid 40116901)
11. Wing K, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science. 2008;322(5899):271-275.
12. Qureshi OS, et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science. 2011;332(6029):600-603.
13. Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol. 2001;19:565-594. (Pubitemid 32368046)
14. Egen JG, Allison JP. Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. Immunity. 2002; 16(1):23-35. (Pubitemid 34143214)
15. Pentcheva-Hoang T, Egen JG, Wojnoonski K, Allison JP. B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse. Immunity. 2004;21(3):401-413. (Pubitemid 39208341)
16. Teft WA, Kirchhof MG, Madrenas J. A molecular perspective of CTLA-4 function. Annu Rev Immunol. 2006;24:65-97.
17. Martin M, Schneider H, Azouz A, Rudd CE. Cytotoxic T lymphocyte antigen 4 and CD28 modulate cell surface raft expression in their regulation of T cell function. J Exp Med. 2001;194(11):1675-1681. (Pubitemid 33126817)
18. Chikuma S, Imboden JB, Bluestone JA. Negative regulation of T cell receptor-lipid raft interaction by cytotoxic T lymphocyte-associated antigen 4. J Exp Med. 2003;197(1):129-135. (Pubitemid 36110264)
19. Hegel JK, Knieke K, Kolar P, Reiner SL, Brunner-Weinzierl MC. CD152 (CTLA-4) regulates effector functions of CD8+ T lymphocytes by repressing Eomesodermin. Eur J Immunol. 2009;39(3):883-893.
20. Pedicord VA, Montalvo W, Leiner IM, Allison JP. Single dose of anti-CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance. Proc Natl Acad Sci U S A. 2011;108(1):266-271.
21. Schneider H, Valk E, da Rocha Dias S, Wei B, Rudd CE. CTLA-4 up-regulation of lymphocyte function-associated antigen 1 adhesion and clustering as an alternate basis for coreceptor function. Proc Natl Acad Sci U S A. 2005;102(36):12861-12866. (Pubitemid 41279456)
22. Wei B, da Rocha Dias S, Wang H, Rudd CE. CTL-associated antigen-4 ligation induces rapid T cell polarization that depends on phosphatidylinositol 3-kinase, Vav-1, Cdc42, and myosin light chain kinase. J Immunol. 2007;179(1):400-408. (Pubitemid 46986557)
23. Schneider H, Valk E, Leung R, Rudd CE. CTLA-4 activation of phosphatidylinositol 3-kinase (PI 3-K) and protein kinase B (PKB/AKT) sustains T-cell anergy without cell death. PLoS One. 2008; 3(12):e3842.
24. Schneider H, et al. Reversal of the TCR stop signal by CTLA-4. Science. 2006;313(5795):1972-1975. (Pubitemid 44498006)
25. Lozanoska-Ochser B, Klein NJ, Huang GC, Alvarez RA, Peakman M. Expression of CD86 on human islet endothelial cells facilitates T cell adhesion and migration. J Immunol. 2008;181(9):6109-6116.
26. Poirier N, et al. Inducing CTLA-4-dependent immune regulation by selective CD28 blockade promotes regulatory T cells in organ transplantation. Sci Transl Med. 2010;2(17):17ra10.
27. Fife BT, et al. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol. 2009;10(11):1185-1192.
28. Demaria S, Bhardwaj N, McBride WH, Formenti SC. Combining radiotherapy and immunotherapy: a revived partnership. Int J Radiat Oncol Biol Phys. 2005;63(3):655-666. (Pubitemid 41400049)
29. Apetoh L, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007; 13(9):1050-1059. (Pubitemid 47517504)
30. Formenti SC, Demaria S. Systemic effects of local radiotherapy. Lancet Oncol. 2009;10(7):718-726.
31. Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol. 2005;174(12):7516-7523. (Pubitemid 40806254)
32. Reits EA, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med. 2006;203(5):1259-1271. (Pubitemid 43736595)
33. Garnett CT, Palena C, Chakraborty M, Tsang KY, Schlom J, Hodge JW. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res. 2004;64(21):7985-7994. (Pubitemid 39446933)
34. Matsumura S, et al. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol. 2008;181(5):3099-3107.
35. Hareyama M, et al. Effect of radiation on the expression of carcinoembryonic antigen of human gastric adenocarcinoma cells. Cancer. 1991;67(9):2269-2274.
36. Gaugler MH, Squiban C, van der Meeren A, Bertho JM, Vandamme M, Mouthon MA. Late and persistent up-regulation of intercellular adhesion molecule-1 (ICAM-1) expression by ionizing radiation in human endothelial cells in vitro. Int J Radiat Biol. 1997;72(2):201-209. (Pubitemid 27339415)
37. Gasser S, Orsulic S, Brown EJ, Raulet DH. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature. 2005;436(7054):1186-1190. (Pubitemid 41232299)
38. Kim JY, et al. Increase of NKG2D ligands and sensitivity to NK cell-mediated cytotoxicity of tumor cells by heat shock and ionizing radiation. Exp Mol Med. 2006;38(5):474-484.
39. Pilones KA, Kawashima N, Yang AM, Babb JS, Formenti SC, Demaria S. Invariant natural killer T cells regulate breast cancer response to radiation and CTLA-4 blockade. Clin Cancer Res. 2009; 15(2):597-606.
40. Jinushi M, Hodi FS, Dranoff G. Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity. Proc Natl Acad Sci U S A. 2006; 103(24):9190-9195. (Pubitemid 43902554)
41. Unutmaz D, Xiang W, Sunshine MJ, Campbell J, Butcher E, Littman DR. The primate lentiviral receptor Bonzo/STRL33 is coordinately regulated with CCR5 and its expression pattern is conserved between human and mouse. J Immunol. 2000; 165(6):3284-3292.
42. Geissmann F, et al. Intravascular immune surveillance by CXCR6+ NKT cells patrolling liver sinusoids. PLoS Biol. 2005;3(4):e113.
43. Shakhar G, et al. Stable T cell-dendritic cell interactions precede the development of both tolerance and immunity in vivo. Nat Immunol. 2005;6(7):707-714. (Pubitemid 41716744)
44. Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest. 2006; 116(7):1935-1945. (Pubitemid 44033317)
45. Stinchcombe JC, Bossi G, Booth S, Griffiths GM. The immunological synapse of CTL contains a secretory domain and membrane bridges. Immunity. 2001; 15(5):751-761. (Pubitemid 34008503)
46. Bilsborough J, Van Pel A, Uyttenhove C, Boon T, Van den Eynde BJ. Identification of a second major tumor-specific antigen recognized by CTLs on mouse mastocytoma P815. J Immunol. 1999; 162(6):3534-3540. (Pubitemid 29313606)
47. Ozato K, Evans GA, Shykind B, Margulies DH, Seidman JG. Hybrid H-2 histocompatibility gene products assign domains recognized by alloreactive T cells. Proc Natl Acad Sci U S A. 1983;80(7):2040-2043. (Pubitemid 13079227)
48. Diefenbach A, Jamieson AM, Liu SD, Shastri N, Raulet DH. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nat Immunol. 2000;1(2):119-126.
49. Ogasawara K, et al. NKG2D blockade prevents autoimmune diabetes in NOD mice. Immunity. 2004; 20(6):757-767. (Pubitemid 38757445)
50. Dustin ML, Bromley SK, Kan Z, Peterson DA, Unanue ER. Antigen receptor engagement delivers a stop signal to migrating T lymphocytes. Proc Natl Acad Sci U S A. 1997;94(8):3909-3913. (Pubitemid 27180472)
51. Beal AM, et al. Protein kinase C theta regulates stability of the peripheral adhesion ring junction and contributes to the sensitivity of target cell lysis by CTL. J Immunol. 2008;181(7):4815-4824.
52. Zhang B, et al. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J Exp Med. 2007;204(1):49-55. (Pubitemid 46148755)
53. Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 1992;52(6):1399-1405.
54. Kim JV, Kang SS, Dustin ML, McGavern DB. Myelomonocytic cell recruitment causes fatal CNS vascular injury during acute viral meningitis. Nature. 2009;457(7226):191-195.
55. Yachi PP, Ampudia J, Gascoigne NR, Zal T. Nonstimulatory peptides contribute to antigen-induced CD8-T cell receptor interaction at the immunological synapse. Nat Immunol. 2005;6(8):785-792. (Pubitemid 43090464)
56. Rosenberg SA, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988;319(25):1676-1680. (Pubitemid 19015247)
57. Mahmoud SM, et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 2011;29(15):1949-1955.
58. Chambers CA, Sullivan TJ, Truong T, Allison JP. Secondary but not primary T cell responses are enhanced in CTLA-4-deficient CD8+ T cells. Eur J Immunol. 1998;28(10):3137-3143. (Pubitemid 28470259)
59. Withers HR. The four R's of radiotherapy. Adv Radiat Biol. 1975;5(3):241-271.
60. Huang JH, et al. Requirements for T lymphocyte migration in explanted lymph nodes. J Immunol. 2007;178(12):7747-7755. (Pubitemid 46898046)
61. Rudd CE. The reverse stop-signal model for CTLA4 function. Nat Rev Immunol. 2008;8(2):153-160. (Pubitemid 351161306)
62. Dillon TJ, Carey KD, Wetzel SA, Parker DC, Stork PJ. Regulation of the small GTPase Rap1 and extracellular signal-regulated kinases by the costimulatory molecule CTLA-4. Mol Cell Biol. 2005; 25(10):4117-4128. (Pubitemid 40617658)
63. Somersalo K, et al. Cytotoxic T lymphocytes form an antigen-independent ring junction. J Clin Invest. 2004;113(1):49-57. (Pubitemid 38541631)
64. Markiewicz MA, et al. Costimulation through NKG2D enhances murine CD8+ CTL function: similarities and differences between NKG2D and CD28 costimulation. J Immunol. 2005;175(5):2825-2833. (Pubitemid 41170499)
65. Diefenbach A, Jensen ER, Jamieson AM, Raulet DH. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature. 2001; 413(6852):165-171. (Pubitemid 32867877)
66. Deguine J, Breart B, Lemaître F, Di Santo JP, Bousso P. Intravital imaging reveals distinct dynamics for natural killer and CD8(+) T cells during tumor regression. Immunity. 2010;33(4):632-644.
67. Gallina G, et al. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest. 2006;116(10):2777- 2790. (Pubitemid 44511641)
68. Bui JD, Carayannopoulos LN, Lanier LL, Yokoyama WM, Schreiber RD. IFN-dependent down-regulation of the NKG2D ligand H60 on tumors. J Immunol. 2006;176(2):905-913. (Pubitemid 43099688)
69. Peggs KS, Quezada SA, Korman AJ, Allison JP. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol. 2006;18(2):206-213. (Pubitemid 43327304)
70. Pulaski BA, Ostrand-Rosenberg S. Mouse 4T1 breast tumor model. Curr Protoc Immunol. 2001; 39(Chapter 20):Unit 20.2.1-20.2.16.
71. Lurquin C, et al. Contrasting frequencies of anti-tumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J Exp Med. 2005;201(2):249-257. (Pubitemid 40189434)
72. Nam JS, et al. An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments. Cancer Res. 2008;68(10):3835-3843.
73. Takaki R, et al. IL-21 enhances tumor rejection through a NKG2D-dependent mechanism. J Immunol. 2005;175(4):2167-2173. (Pubitemid 41113822)
74. Groh V, Bahram S, Bauer S, Herman A, Beauchamp M, Spies T. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc Natl Acad Sci U S A. 1996;93(22):12445- 12450. (Pubitemid 26367163)
75. Hoos A, et al. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin Oncol. 2010;37(5):533-546.
76. Dewan MZ, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res. 2009;15(17):5379-5388.
77. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271(5256):1734-1736.
78. von Andrian UH. Intravital microscopy of the peripheral lymph node microcirculation in mice. Microcirculation. 1996;3(3):287-300.
79. Vijh S, Pilip IM, Pamer EG. Effect of antigen-processing efficiency on in vivo T cell response magnitudes. J Immunol. 1998;160(8):3971-3977. (Pubitemid 28176105)
80. Bromley SK, Peterson DA, Gunn MD, Dustin ML. Cutting edge: hierarchy of chemokine receptor and TCR signals regulating T cell migration and proliferation. J Immunol. 2000;165(1):15-19.
81. Champsaur M, Lanier LL. Effect of NKG2D ligand expression on host immune responses. Immunol Rev. 2010;235(1):267-285.
82. Lindquist RL, et al. Visualizing dendritic cell networks in vivo. Nat Immunol. 2004;5(12):1243-1250. (Pubitemid 41057739)
83. Hugues S, Fetler L, Bonifaz L, Helft J, Amblard F, Amigorena S. Distinct T cell dynamics in lymph nodes during the induction of tolerance and immunity. Nat Immunol. 2004;5(12):1235-1242. (Pubitemid 41057738)
84. Miller MJ, Wei SH, Parker I, Cahalan MD. Two-photon imaging of lymphocyte motility and antigen response in intact lymph node. Science. 2002; 296(5574):1869-1873. (Pubitemid 34596273)
85. Quezada SA, Peggs KS, Simpson TR, Shen Y, Littman DR, Allison JP. Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J Exp Med. 2008;205(9):2125-2138.
86. Laird NM, Donnelly C, Ware JH. Longitudinal studies with continuous responses. Stat Methods Med Res. 1992;1(3):225-247.